0	12	Phenylarsine	Phenylarsine	NNP
13	18	oxide	oxide	NN
19	27	inhibits	inhibit	VBZ
28	30	ex	ex	FW
31	35	vivo	vivo	FW
36	41	HIV-1	HIV-1	NNP
42	52	expression	expression	NN
52	53	.	.	.

55	67	Phenylarsine	Phenylarsine	NNP
68	73	oxide	oxide	NN
74	75	(	(	(
75	78	PAO	PAO	NNP
78	79	)	)	)
79	80	,	,	,
81	86	which	which	WDT
87	89	is	be	VBZ
90	99	described	describe	VBN
100	102	as	as	IN
103	105	an	an	DT
106	115	inhibitor	inhibitor	NN
116	118	of	of	IN
119	127	tyrosine	tyrosine	NN
128	139	phosphatase	phosphatase	NN
140	148	activity	activity	NN
148	149	,	,	,
150	158	inhibits	inhibit	VBZ
159	163	H2O2	h2o2	NN
164	171	release	release	NN
172	176	from	from	IN
177	182	human	human	JJ
183	193	peripheral	peripheral	JJ
194	199	blood	blood	NN
200	211	mononuclear	mononuclear	JJ
212	217	cells	cell	NNS
218	219	(	(	(
219	224	PBMCs	PBMC	NNP
224	225	)	)	)
226	228	as	as	IN
229	237	measured	measure	VBN
238	240	by	by	IN
241	257	electrochemistry	electrochemistry	NN
257	258	.	.	.

259	264	Since	since	IN
265	270	human	human	JJ
271	287	immunodeficiency	immunodeficiency	NN
288	293	virus	virus	NN
294	298	type	type	NN
299	300	1	1	CD
301	302	(	(	(
302	307	HIV-1	HIV-1	NNP
307	308	)	)	)
309	320	replication	replication	NN
321	323	is	be	VBZ
324	329	known	know	VBN
330	332	to	to	TO
333	335	be	be	VB
336	343	favored	favor	VBN
344	349	under	under	IN
350	359	oxidative	oxidative	JJ
360	366	stress	stress	NN
367	377	conditions	condition	NNS
377	378	,	,	,
379	381	ex	ex	FW
382	386	vivo	vivo	FW
387	398	experiments	experiment	NNS
399	404	using	use	VBG
405	415	uninfected	uninfected	JJ
416	421	PBMCs	pbmc	NNS
421	422	,	,	,
423	430	primary	primary	JJ
431	440	monocytes	monocyte	NNS
441	443	or	or	CC
444	445	a	a	DT
446	454	latently	latently	RB
455	463	infected	infected	JJ
464	476	promonocytic	promonocytic	JJ
477	479	U1	u1	NN
480	484	cell	cell	NN
485	489	line	line	NN
490	494	show	show	VBP
495	499	that	that	IN
500	505	HIV-1	HIV-1	NNP
506	517	replication	replication	NN
518	521	and	and	CC
522	534	reactivation	reactivation	NN
534	535	,	,	,
536	545	monitored	monitor	VBN
546	548	by	by	IN
549	552	p24	p24	NN
553	560	antigen	antigen	NN
561	572	measurement	measurement	NN
572	573	,	,	,
574	577	are	be	VBP
578	587	inhibited	inhibit	VBN
588	590	by	by	IN
591	594	PAO	PAO	NNP
595	597	in	in	IN
598	599	a	a	DT
600	605	time-	time-	NN
606	609	and	and	CC
610	633	concentration-dependent	concentration-dependent	JJ
634	640	manner	manner	NN
640	641	.	.	.

642	647	These	these	DT
648	660	observations	observation	NNS
661	664	can	can	MD
665	667	be	be	VB
668	674	linked	link	VBN
675	679	with	with	IN
680	683	the	the	DT
684	694	inhibition	inhibition	NN
695	697	of	of	IN
698	706	NF-kappa	NF-kappa	NNP
707	708	B	B	NNP
709	719	activation	activation	NN
720	724	when	when	WRB
725	735	uninfected	uninfected	JJ
736	745	monocytes	monocyte	NNS
746	749	are	be	VBP
750	757	induced	induce	VBN
758	760	by	by	IN
761	767	either	either	CC
768	773	tumor	tumor	NN
774	782	necrosis	necrosis	NN
783	789	factor	factor	NN
790	795	alpha	alpha	NN
796	797	(	(	(
797	806	TNF-alpha	TNF-alpha	NNP
806	807	)	)	)
808	815	phorbol	phorbol	NN
816	828	12-myristate	12-myristate	NN
829	839	13-acetate	13-acetate	NN
840	841	(	(	(
841	844	PMA	PMA	NNP
844	845	)	)	)
846	848	or	or	CC
849	867	lipopolysaccharide	lipopolysaccharide	NN
868	869	(	(	(
869	872	LPS	LPS	NNP
872	873	)	)	)
873	874	.	.	.